Navigation Links
HMS Holdings Corp. to Present at Credit Suisse Annual Global Healthcare Conference
Date:11/6/2008

NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- HMS Holdings Corp. (Nasdaq: HMSY) today announced that it will present at the Credit Suisse Annual Global Healthcare Conference, which will be held November 12-14, 2008 at the Arizona Biltmore Hotel in Phoenix, AZ.

Robert Holster, CEO and Walter Hosp, CFO, will present on Wednesday, November 12th at 11:00 am MST.

HMS Holdings Corp. (Nasdaq: HMSY) is the nation's leader in coordination of benefits and program integrity services for government healthcare programs. The company's clients include health and human services programs in more than 40 states, 80 Medicaid managed care plans, the Centers for Medicare and Medicaid Services (CMS), and Veterans Administration facilities. HMS helps ensure that healthcare claims are paid correctly and by the responsible party. As a result of the company's services, government healthcare programs recover over $1 billion annually, and avoid billions of dollars more in erroneous payments.


'/>"/>
SOURCE HMS Holdings Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008
2. HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance
3. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
4. XELR8 Holdings Announces Conference Call to Review Third Quarter Financial Results
5. China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination
6. HMS Holdings Corp. to Present at Oppenheimer 19th Annual Healthcare Conference
7. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results
8. MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.
9. Z Trim Holdings, Inc. Releases Letter to Shareholders
10. Z Trim Holdings, Inc. Announces Private Placement Funding
11. MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 3Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 4Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 5Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 6Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 7Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 2Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 3Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Scientific Publications Strategy & Delivery Shifts from Marketing to Medical 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 3Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 4
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2